Radiologists Can't Spot AI Deepfake X-Rays, Study Finds
A 2026 Radiology study reveals board-certified radiologists cannot reliably detect AI-generated chest X-rays, raising serious patient safety concerns.
By Priya Patel
Medical Technology
The latest medical technology coverage from Hawaii Medical Journal.
Doctronic Raises $40M Series B to Expand AI Clinical Care
Doctronic, an AI-assisted telehealth startup, closed a $40M Series B in March 2026, bringing total funding to $65M in under twelve months.
By Priya Patel
How Digital Marketplaces Are Reshaping Lab Procurement in 2026
As biotech and pharmaceutical teams grapple with fragmented vendor networks and chronic supply delays, a new class of digital procurement marketplaces is emerging to streamline how labs order everything from reagents to research equipment.
By Priya Patel
Somatic Loss of Y Chromosome as a Complementary Risk Factor in Type 2 Diabetes Prediction: Evidence from East Asian Population Analysis
A recent Nature Medicine study demonstrates that somatic loss of the Y chromosome significantly increases type 2 diabetes risk in East Asian men, particularly those with low polygenic risk scores, with direct evidence of Y chromosome loss in pancreatic β-cells.
Federal Policy Restrictions and the Decline of Human Fetal Tissue Research: Implications for Translational Medicine and Vaccine Development
Analysis of recent federal funding restrictions reveals substantial decline in human fetal tissue research support, with implications for developmental biology studies, vaccine production, and disease modeling capabilities.
Large Language Model Evidence Gaps in Clinical Medicine: A Systematic Review Reveals Limited Real-World Validation
An LLM-assisted systematic review of 4,609 clinical studies published between 2022-2025 demonstrates that only 22.7% utilized real-world patient data, with merely 19 prospective randomized trials conducted. The analysis reveals substantial evidence gaps despite rapid proliferation of medical AI research at 3.2 publications per day.
In Vivo PCSK9 Base Editing Demonstrates Proof-of-Concept for Familial Hypercholesterolemia: A Critical Assessment of Phase 1 Trial Results
A phase 1 clinical trial of liver-targeted PCSK9 base editing demonstrates preliminary efficacy for familial hypercholesterolemia treatment, though significant optimization challenges remain for clinical translation. The study represents an important milestone in applying CRISPR-based therapeutics to cardiovascular disease management.